A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

By afschroeder • June 10, 2026

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams C, Schweitzer C, Adhikary S, Jung AS, Klebanoff CA. A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial). Front Oncol. 2026 May 21;16:1809354. doi: 10.3389/fonc.2026.1809354. PMID: 42266673; PMCID: PMC13244869.

Tags: adoptive cell therapy (ACT), cell surface receptor drug targets, clinical trial results, Hematology/Oncology, immunotherapy, Publications, T-cell receptor (TCR)

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]

The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need to Know

Graham DM, Lofftus S, Azizi L, Berkowitz MJ, Teshome M. The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need[...]

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]